Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin
Roberto Contieri(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Charles C. Guo(The University of Texas MD Anderson Cancer Center), Valentina Grajales(The University of Texas MD Anderson Cancer Center), Graciela M. Nogueras‐González(The University of Texas MD Anderson Cancer Center), Alberto Martini(The University of Texas MD Anderson Cancer Center), Patrick J. Hensley(University of Kentucky), Niyati Lobo(The University of Texas MD Anderson Cancer Center), Kelly K. Bree(The University of Texas MD Anderson Cancer Center), Neema Navai(The University of Texas MD Anderson Cancer Center), Wei Shen Tan, Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Cited by 15
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
|Cancer Discovery|2018|570
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Epidemiology, Screening, and Prevention of Bladder Cancer
|European Urology Oncology|2022|361